MX2015009403A - Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox. - Google Patents
Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox.Info
- Publication number
- MX2015009403A MX2015009403A MX2015009403A MX2015009403A MX2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compound
- compositions
- oxidative stress
- pathological conditions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000036542 oxidative stress Effects 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- -1 sulphide compound Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013626 chemical specie Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical class C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 150000004763 sulfides Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/751,429 US20130136725A1 (en) | 2002-06-19 | 2013-01-28 | Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| PCT/MX2014/000029 WO2014116097A2 (es) | 2013-01-28 | 2014-01-28 | Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015009403A true MX2015009403A (es) | 2017-07-04 |
Family
ID=51228167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009403A MX2015009403A (es) | 2013-01-28 | 2014-01-28 | Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2949332A4 (enExample) |
| JP (1) | JP2016508996A (enExample) |
| KR (1) | KR20160140331A (enExample) |
| CN (1) | CN105228633A (enExample) |
| AU (1) | AU2014210447A1 (enExample) |
| BR (1) | BR112015017440A2 (enExample) |
| CA (1) | CA2898596A1 (enExample) |
| HK (1) | HK1217175A1 (enExample) |
| MX (1) | MX2015009403A (enExample) |
| WO (1) | WO2014116097A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102835427B1 (ko) | 2017-10-25 | 2025-07-21 | 4틴4 파마슈티컬스 게엠베하 | 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도 |
| WO2020147830A1 (en) * | 2019-01-19 | 2020-07-23 | Goldred Nanobiotech Co., Ltd. | Ocular lens, pharmaceutical composition, and uses thereof |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| US20230213519A1 (en) | 2020-03-16 | 2023-07-06 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| US20260201067A1 (en) | 2022-12-15 | 2026-07-16 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
| JP2026513177A (ja) | 2023-03-29 | 2026-04-23 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤 |
| WO2025247952A1 (en) * | 2024-05-30 | 2025-12-04 | Université De Fribourg | Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4148885A (en) | 1973-09-25 | 1979-04-10 | Institut Merieux | Immunostimulant medicine |
| JPS59118709A (ja) | 1982-12-27 | 1984-07-09 | Suntory Ltd | 効力を増強しかつ低毒化せしめた抗腫瘍組成物 |
| DE3419686A1 (de) | 1983-05-26 | 1984-11-29 | T and R Chemicals, Inc., Clint, Tex. | Verwendung einer zusammensetzung mit therapeutischer wirksamkeit |
| IL81166A (en) | 1987-01-05 | 1990-03-19 | Kaplan Ephraim | Pharmaceutically active combination comprising an ionic vanadium compound and thiosulfate or sulfite compound and optionally selenium |
| US8361514B2 (en) * | 2002-06-19 | 2013-01-29 | Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| JP5063878B2 (ja) * | 2005-08-30 | 2012-10-31 | 扶桑薬品工業株式会社 | 硫化水素塩を含有する消化器系疾患の予防／治療用組成物 |
| JP5905387B2 (ja) * | 2009-07-08 | 2016-04-20 | ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズＨｏｐｅ Ｍｅｄｉｃａｌ Ｅｎｔｅｒｐｒｉｓｅｓ，Ｉｎｃ．Ｄｂａ Ｈｏｐｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ | チオ硫酸ナトリウムを含有する薬学的組成物 |
-
2014
- 2014-01-28 BR BR112015017440A patent/BR112015017440A2/pt not_active Application Discontinuation
- 2014-01-28 CN CN201480018525.6A patent/CN105228633A/zh active Pending
- 2014-01-28 HK HK16105188.3A patent/HK1217175A1/zh unknown
- 2014-01-28 AU AU2014210447A patent/AU2014210447A1/en not_active Abandoned
- 2014-01-28 JP JP2015555120A patent/JP2016508996A/ja active Pending
- 2014-01-28 WO PCT/MX2014/000029 patent/WO2014116097A2/es not_active Ceased
- 2014-01-28 CA CA2898596A patent/CA2898596A1/en not_active Abandoned
- 2014-01-28 EP EP14743853.5A patent/EP2949332A4/en not_active Withdrawn
- 2014-01-28 KR KR1020157023387A patent/KR20160140331A/ko not_active Ceased
- 2014-01-28 MX MX2015009403A patent/MX2015009403A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2949332A4 (en) | 2016-07-27 |
| KR20160140331A (ko) | 2016-12-07 |
| WO2014116097A2 (es) | 2014-07-31 |
| BR112015017440A2 (pt) | 2017-07-11 |
| CA2898596A1 (en) | 2014-07-31 |
| WO2014116097A3 (es) | 2014-12-04 |
| CN105228633A (zh) | 2016-01-06 |
| AU2014210447A1 (en) | 2015-08-20 |
| EP2949332A2 (en) | 2015-12-02 |
| HK1217175A1 (zh) | 2016-12-30 |
| JP2016508996A (ja) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014116097A3 (es) | Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox | |
| MX365950B (es) | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. | |
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| HK1209633A1 (en) | Compositions and methods for treating diabetes | |
| EA201491819A1 (ru) | Фармацевтические композиции для комбинированного лечения | |
| EA200901212A1 (ru) | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний | |
| WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
| EA201170349A1 (ru) | Модуляторы mif | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
| MX2015001250A (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
| MX2015005548A (es) | Tratamiento de cancer con pomalidomida en un individuo con daño renal. | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| DK2714888T3 (da) | Rekombinant gær | |
| EA201291329A1 (ru) | Гетероциклические соединения, их получение и их терапевтическое применение | |
| EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
| MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| EA201170447A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 |